Cancer Biomarker Map for Fenbendazole, Mebendazole, Ivermectin, Niclosamide & Atovaquone: A Comparative Mechanistic Analysis for Precision Oncology
Drug repurposing has generated substantial interest in oncology because a number of established medicines originally developed for infections or other diseases have demonstrated anticancer activity in laboratory models. Fenbendazole, mebendazole, ivermectin, niclosamide and atovaquone are five examples that have attracted attention for very different mechanistic reasons.
But the phrase “repurposed cancer drug” can easily hide a major scientific problem: these compounds are not molecular equivalents. Some act primarily on microtubules. Others influence signaling pathways, p53 regulation or cellular metabolism. Atovaquone is particularly different because its oncology rationale is closely tied to mitochondrial respiration and tumor hypoxia rather than a conventional mutation-specific target.
This article therefore expands the original three-drug biomarker map of fenbendazole, mebendazole and ivermectin to include niclosamide and atovaquone. The objective is not to create a list of alternative cancer treatments. It is to build a research-oriented framework linking drug → molecular target → biomarker or phenotype → cancer context → resistance hypothesis.
- 1. Why a Biomarker Map Is Better Than a Drug List
- 2. Evidence-Grading System
- 3. Comparative Master Biomarker Map
- 4. Fenbendazole: p53, MDM2/MDMX, KRAS and Metabolism
- 5. Mebendazole: Tubulin, Mitotic Vulnerability and Tumor Stroma
- 6. Ivermectin: PAK1, YAP1, Wnt and PI3K/Akt/mTOR
- 7. Niclosamide: Wnt, STAT3, AR-V7 and Metabolism
- 8. Atovaquone: OXPHOS, Complex III and Tumor Hypoxia
- 9. Drug Repurposing and Cancer Treatment Resistance
- 10. Comparative Cancer-Type Map
- 11. The Five-Drug Oncology Architecture
- 12. Highest-Priority Research Hypotheses
- 13. Pharmacology and Translational Limitations
- 14. What Would Clinical Validation Require?
- 15. Conclusion
- 16. Frequently Asked Questions
- 17. Scientific References
1. Why a Biomarker Map Is Better Than a Drug List
Precision oncology starts from a simple observation: cancer is not one disease. Two tumors arising in the same organ can have different driver mutations, tumor-suppressor status, signaling dependencies, metabolic programs, immune environments and mechanisms of treatment resistance.
That principle matters even more when evaluating drug repurposing. A drug may demonstrate activity in a cancer model without having a single universal mechanism. Conversely, a compound with modest activity across an unselected population may theoretically become more interesting if a biologically coherent vulnerable subgroup can be identified.
The five compounds in this article illustrate five overlapping but distinct regions of cancer biology:
p53 regulation microtubules oncogenic signaling glycolysis mitochondrial metabolism tumor hypoxia cancer stem-like states treatment resistance
Fenbendazole is particularly interesting because of experimental connections between benzimidazole treatment, wild-type p53 activity, MDM2/MDMX and metabolic effects. Mebendazole is more strongly centered on tubulin and cell division, although additional kinase, apoptotic, angiogenic and stromal mechanisms have been investigated. Ivermectin has a more signaling-network-oriented profile involving PAK1, YAP1/Hippo, Wnt and Akt/mTOR.
Niclosamide adds a broader signaling and metabolic axis involving Wnt/β-catenin, STAT3, mTOR, NF-κB, Notch and mitochondrial biology.
Atovaquone is conceptually different again. Its oncology rationale includes inhibition of mitochondrial complex III and oxidative phosphorylation, potentially decreasing oxygen consumption and reducing tumor hypoxia. Importantly, this hypothesis has reached human pharmacodynamic testing in non-small-cell lung cancer.
2. Evidence-Grading System
To avoid turning mechanistic speculation into implied clinical certainty, this article uses the following evidence framework.
| Grade | Meaning | How to interpret it |
|---|---|---|
| A | Direct drug-specific experimental evidence in a defined biomarker or phenotype context. | Strong research signal, but still not clinical validation. |
| B | Strong drug-specific mechanistic evidence with incomplete predictive-biomarker validation. | Promising research hypothesis. |
| C | Indirect, pathway-overlap, related-model or exploratory evidence. | Hypothesis-generating only. |
| D | Insufficient drug-specific evidence to regard the biomarker as predictive. | Should not be presented as a validated selection biomarker. |
3. Comparative Master Biomarker Map
| Biomarker / Phenotype | Fenbendazole | Mebendazole | Ivermectin | Niclosamide | Atovaquone | Interpretation |
|---|---|---|---|---|---|---|
| TP53 wild-type | A | B/C | C | C | D/C | Strongest p53-centered rationale is with fenbendazole. |
| TP53 mutant | C | C | C | C | C | Mutation alone should not be interpreted as sensitivity or resistance. |
| MDM2 high / amplified + TP53-WT | A/B | C | D/C | C | D | Distinctive fenbendazole research hypothesis. |
| MDM4 / MDMX high + TP53-WT | A | C | D/C | C | D | Particularly interesting p53-regulatory phenotype for FBZ research. |
| KRAS-mutant | A in selected lung models | B in selected pancreatic models | C | C | C | Not a universal KRAS-directed strategy. |
| EGFR-mutant | D/C | C | C | C | C | No validated drug-specific EGFR biomarker. |
| MYC-high | B | C | C/B | B/C | C | Exploratory network-level association. |
| GLUT1 / high glucose uptake | B | C | C | B/C | C | Metabolic vulnerability hypothesis. |
| HK2-high / glycolysis | A/B | C/B | C | B/C | C | Metabolic phenotype of interest, strongest experimental rationale for FBZ. |
| PAK1-high | D | D/C | A/B | C | D | Distinctive ivermectin-centered hypothesis. |
| YAP1-high / Hippo dysregulation | D | C | A/B | C | D/C | Strongest association is with ivermectin literature. |
| Wnt/β-catenin activation | C | B/C | A/B | A/B | C/D | Shared pathway concept, particularly prominent for IVM and niclosamide. |
| STAT3-active | C | C | B | A/B | C | Strong experimental niclosamide and ivermectin rationale. |
| PI3K/Akt/mTOR-active | C | C/B | A/B | B | C | Most characteristic of ivermectin and niclosamide literature. |
| AR-V7 / androgen-receptor resistance | D | D | C | A/B | D | Important niclosamide prostate-cancer research axis. |
| Microtubule dependence | A | A | B/C | C | D | Shared major property of the benzimidazoles. |
| Cancer stem-like phenotype | C | C | B | B | B/C | Multiple compounds have been investigated against stem-like states. |
| OXPHOS dependence | C | C | C/B | B/C | A/B | Strongest direct mitochondrial rationale is atovaquone. |
| Tumor hypoxia | D | D/C | C | C/B | A | Atovaquone is the clearest hypoxia-modifying research candidate. |
| Hypoxia-related resistance | D | C | C | C | A/B | Atovaquone may be more valuable as a microenvironment modifier than as a stand-alone cytotoxic agent. |
↔ Swipe the table sideways to see all columns on mobile.
These grades describe the strength of a drug-biomarker research hypothesis, not the strength of clinical evidence for treating patients.
4. Fenbendazole: p53, MDM2/MDMX, KRAS and Metabolism
4.1 The p53–MDM2–MDMX axis
Fenbendazole is a benzimidazole anthelmintic. One of the most distinctive experimental observations associated with fenbendazole involves the p53 regulatory network.
In a screening and mechanistic study, fenbendazole increased p53 and p21 while decreasing MDM2 and MDMX in melanoma and breast-cancer cells overexpressing these negative regulators. The investigators interpreted the findings as activation of wild-type p53 through downregulation of p53's negative regulators.
The important point is that fenbendazole should not be described as an established selective MDM2 inhibitor. The experimental study demonstrated changes in MDM2/MDMX protein levels and p53 activity; that is different from demonstrating a clinically validated MDM2-targeted drug mechanism.
4.2 Why TP53-WT may matter more than TP53 status alone
A more specific research hypothesis is therefore:
This phenotype is more biologically coherent than simply saying “p53-positive cancer.” A tumor can retain a wild-type TP53 gene while having the pathway functionally suppressed by negative regulators such as MDM2 and MDMX.
That makes the pathway potentially interesting for biomarker-stratified research—but it has not been validated prospectively as a patient-selection strategy.
4.3 KRAS-mutant lung cancer
Fenbendazole has also been investigated in lung-cancer models in which genotype and metabolic phenotype interact. The existence of activity in KRAS-mutant experimental systems should not be translated into the statement that all KRAS-mutant cancers are sensitive to fenbendazole.
KRAS is a signaling driver shared across multiple tumor types, but KRAS-mutant tumors can differ dramatically in co-mutations, lineage, differentiation, immune microenvironment and metabolic state.
Accordingly:
4.4 Glucose metabolism and HK2
Another experimental theme is altered tumor glucose utilization. Hexokinase 2 (HK2) is a major glycolytic enzyme frequently associated with malignant metabolic reprogramming. Experimental fenbendazole work has reported effects on glucose uptake and glycolytic metabolism.
This suggests a potential phenotype of:
high glycolytic activity + HK2 dependence + additional drug-specific vulnerabilities
Again, the important distinction is between biological plausibility and clinical predictive validation.
4.5 Fenbendazole's experimental identity
| Layer | Fenbendazole research hypothesis |
|---|---|
| Genetic | TP53-WT, selected KRAS-mutant models |
| Regulatory | MDM2 / MDMX elevation |
| Metabolic | GLUT1 / HK2 / glycolytic phenotype |
| Structural | Microtubule disruption |
| Cellular | Cell-cycle arrest, stress and apoptosis |
5. Mebendazole: Tubulin, Mitotic Vulnerability and Tumor Stroma
5.1 Microtubules remain the central mechanism
Mebendazole and fenbendazole share a benzimidazole scaffold, but it is inappropriate to assume that all of their cancer effects are interchangeable.
Mebendazole has long-standing experimental evidence for disruption of tubulin and microtubule-dependent cell division. In non-small-cell lung-cancer models, treatment produced abnormal spindle formation, mitotic arrest, caspase activation and cytochrome-c release, supporting a mechanism involving mitotic disruption followed by apoptosis.
5.2 Bcl-2 and apoptosis
Mebendazole has also been studied in chemoresistant melanoma models in which apoptotic signaling involved Bcl-2 phosphorylation and altered interaction with pro-apoptotic proteins.
This is important because it demonstrates why “benzimidazole” should not be treated as a single mechanistic category. Two chemically related compounds can engage different downstream vulnerabilities.
5.3 MAPK14 / p38α
Mebendazole has also been investigated in relation to MAPK14, commonly known as p38α. This pathway may represent a secondary signaling vulnerability rather than a universal biomarker.
The current evidence is better described as a drug-specific mechanistic hypothesis than as a clinically validated MAPK14 biomarker.
5.4 Pancreatic cancer and desmoplasia
Pancreatic ductal adenocarcinoma is particularly interesting because malignant cells exist within a dense stromal microenvironment. Preclinical work in genetically engineered pancreatic-cancer models examined whether mebendazole could influence tumor initiation, stromal desmoplasia, tumor growth and metastasis.
This creates a different framework:
That distinction is useful for the broader Cancer Advisor knowledge graph because not every resistance mechanism is encoded by a tumor-cell mutation. The microenvironment can be equally important.
5.5 Mebendazole's experimental identity
| Layer | Mebendazole research hypothesis |
|---|---|
| Structural | Microtubule / tubulin disruption |
| Cell cycle | Mitotic arrest and mitotic catastrophe |
| Apoptosis | Bcl-2-associated mechanisms, caspases and mitochondrial pathways |
| Signaling | MAPK14 / p38α and other kinase effects |
| Microenvironment | Stromal and desmoplastic effects in pancreatic cancer models |
6. Ivermectin: PAK1, YAP1, Wnt and PI3K/Akt/mTOR
Ivermectin belongs to a different pharmacological family from the benzimidazoles. Its experimental oncology literature is consequently better viewed as a signaling-network map than as a simple microtubule story.
Reviews of the literature describe effects involving PAK1, Wnt/β-catenin, Hippo/YAP, Akt/mTOR, multidrug resistance mechanisms, autophagy, apoptosis and cancer stem-like cells.
6.1 PAK1
PAK1, or p21-activated kinase 1, is an important signaling protein connected to cytoskeletal remodeling, proliferation and survival signaling.
The experimental ivermectin literature has repeatedly highlighted PAK1 as a distinctive molecular target. This makes PAK1-high or PAK1-dependent tumors an interesting research phenotype.
6.2 YAP1 / Hippo signaling
Another prominent experimental theme is YAP1. In gastric-cancer models, ivermectin was investigated as a YAP1-associated inhibitor and YAP1 expression was linked experimentally to drug sensitivity.
The corresponding research phenotype is:
6.3 Wnt/β-catenin
Wnt signaling is especially relevant to cancer stemness, proliferation and resistance. Experimental ivermectin studies have reported suppression of Wnt/TCF signaling and changes in Wnt-associated genes including AXIN2, LGR5 and ASCL2.
This makes Wnt/β-catenin one of ivermectin's most recurrent pathway-level hypotheses.
6.4 PI3K/Akt/mTOR
Ivermectin has also been linked experimentally to the PI3K/Akt/mTOR axis and downstream changes in cell survival, autophagy and apoptosis.
Because PI3K/Akt/mTOR signaling is ubiquitous across many tumor types, however, pathway activation alone would be a weak predictive biomarker without drug-specific clinical validation.
6.5 Cancer stem-like states
Multiple studies have explored ivermectin's effects on cancer stem-like populations. This is particularly relevant to treatment resistance because stem-like states may contribute to persistence, relapse and metastatic competence.
However, “cancer stem cells” should be regarded here as an experimental phenotype rather than a standardized clinical biomarker.
| Ivermectin axis | Research phenotype | Evidence interpretation |
|---|---|---|
| PAK1 | PAK1-high signaling | Distinct drug-specific hypothesis |
| YAP1 / Hippo | YAP1-high tumors | Particularly interesting in gastric-cancer models |
| Wnt/β-catenin | Wnt-active / stemness phenotype | Repeated preclinical pathway evidence |
| PI3K/Akt/mTOR | Survival signaling activation | Repeated mechanistic association |
| CSC phenotype | Stem-like / self-renewing cells | Experimental, not a validated clinical marker |
7. Niclosamide: Wnt, STAT3, AR-V7 and Metabolism
Niclosamide is one of the most important additions to the expanded framework because it demonstrates how a repurposed antihelminthic can intersect with multiple oncogenic pathways while simultaneously exposing the importance of pharmacokinetics.
Experimental studies and reviews have described effects on Wnt/β-catenin, STAT3, mTORC1, NF-κB, Notch and mitochondrial function.
7.1 Wnt/β-catenin
Niclosamide has repeatedly been investigated as a Wnt pathway inhibitor. Wnt activation is particularly important in colorectal cancer, stemness and therapy resistance.
This makes the following a reasonable experimental hypothesis:
That should not be interpreted as evidence that patients with Wnt activation should receive niclosamide.
7.2 STAT3
STAT3 is another potentially important node. Experimental cancer studies have reported suppression of STAT3 signaling by niclosamide, including in chemoresistant tumor models. Work in colorectal cancer has explored niclosamide alongside chemotherapy-related pathways.
The resulting research phenotype can be represented as:
7.3 AR-V7 and castration-resistant prostate cancer
Niclosamide has also attracted attention in metastatic castration-resistant prostate cancer because of experimental activity against androgen-receptor splice variants, including AR-V7.
This pathway is particularly interesting because AR-V7 has been associated with treatment resistance in prostate cancer.
But the human studies provide an important cautionary lesson.
7.4 The pharmacokinetic problem
A phase I study evaluated conventional oral niclosamide combined with enzalutamide in men with metastatic castration-resistant prostate cancer. The trial enrolled only five patients after screening, and higher dosing produced dose-limiting gastrointestinal toxicities. The maximum tolerated dose did not consistently achieve the plasma concentrations thought necessary from preclinical models, and the study was closed for futility.
This is one of the most important drug-repurposing lessons in the entire article:
A pathway can be biologically important. A drug can inhibit that pathway in a laboratory. Yet the drug may still fail clinically if the required exposure cannot be achieved safely.
7.5 Reformulated niclosamide
Subsequent work has explored reformulated, more bioavailable niclosamide formulations. A phase Ib study combining reformulated niclosamide with abiraterone and prednisone enrolled nine men with metastatic castration-resistant prostate cancer and primarily addressed dose, safety and pharmacokinetic questions.
This does not establish efficacy, but it demonstrates the importance of formulation in drug repurposing.
7.6 Niclosamide and mitochondrial metabolism
Niclosamide has also been described experimentally as affecting mitochondrial function and oxidative phosphorylation. This overlaps conceptually with the metabolic framework surrounding atovaquone, but the two drugs should not be considered interchangeable mitochondrial inhibitors.
Niclosamide's experimental identity is better described as:
| Niclosamide axis | Potential research phenotype |
|---|---|
| Wnt/β-catenin | Wnt-high / stemness-associated tumor biology |
| STAT3 | STAT3-active / survival-signaling phenotype |
| AR signaling | AR-V7 / treatment-resistant CRPC |
| mTOR | mTOR-active tumors |
| Mitochondria | Metabolic vulnerability |
| Formulation / exposure | Pharmacokinetic feasibility is itself a development variable |
8. Atovaquone: OXPHOS, Complex III and Tumor Hypoxia
Atovaquone may be the most conceptually valuable addition to this framework because it moves the analysis beyond tumor-cell genetics into tumor physiology and the microenvironment.
Atovaquone is an established anti-infective drug that inhibits mitochondrial electron transport, particularly complex III. Experimental work has shown inhibition of oxygen consumption and oxidative phosphorylation and has investigated effects on cancer stem-like populations.
8.1 The OXPHOS hypothesis
But the most clinically interesting implication may not be direct tumor-cell killing.
8.2 Tumor hypoxia
Tumor hypoxia is a major feature of many aggressive cancers and has been associated with treatment resistance, altered metabolism, angiogenesis, invasion and immune dysfunction.
A clinical study in patients with resectable non-small-cell lung cancer specifically evaluated whether atovaquone could reduce tumor hypoxia. Patients received standard-dose atovaquone for a median treatment period of 12 days.
Thirty patients were evaluable for hypoxia PET-CT analysis, with 15 treated and 15 untreated. Among treated patients, 11 of 15 had a meaningful reduction in hypoxic volume, with a median change of −28%. The study also found reductions in hypoxia-related gene expression.
This is important because it represents human pharmacodynamic evidence rather than only cell-line or mouse data.
It still does not demonstrate improved survival or prove that atovaquone is an effective standalone cancer treatment.
8.3 Hypoxia as a biomarker
Atovaquone suggests a broader concept for precision oncology:
Potential research measurements include:
| Hypoxia-related measurement | Potential role |
|---|---|
| Hypoxia PET | Direct imaging of tumor hypoxic burden |
| Hypoxia gene signatures | Measurement of transcriptional response to low oxygen |
| HIF pathway activity | Assessment of hypoxia-inducible signaling |
| Oxygen-enhanced MRI | Alternative assessment of tumor oxygenation |
| OXPHOS signatures | Assessment of mitochondrial respiratory dependence |
8.4 Atovaquone and treatment resistance
Hypoxia is relevant to cancer resistance because low oxygen can alter DNA-damage responses, metabolism, cell survival and sensitivity to radiation.
That creates an intriguing combination hypothesis:
Radiotherapy is one of the most obvious research contexts because oxygen availability is directly relevant to radiation-induced tumor damage.
Preclinical studies have also explored whether reducing tumor hypoxia could improve anti-PD-1 responses, but such findings remain preclinical and should not be interpreted as proof that atovaquone improves immunotherapy outcomes in patients.
8.5 Atovaquone is not simply “another antiparasitic cancer drug”
This distinction is important enough to state explicitly.
Atovaquone should be viewed primarily as an experimental mitochondrial and tumor-microenvironment modifier.
Its most compelling research phenotype may therefore be:
rather than:
“a specific mutation that makes the tumor sensitive.”
9. Drug Repurposing and Cancer Treatment Resistance
Cancer treatment resistance is rarely caused by one mechanism. Resistance can emerge from genetic evolution, epigenetic changes, pathway rewiring, altered metabolism, drug efflux, tumor heterogeneity and changes in the tumor microenvironment.
This is where the five-drug map becomes more interesting than a conventional drug list.
| Resistance problem | Potential experimental axis | Most relevant research candidates |
|---|---|---|
| p53 suppression despite TP53-WT | MDM2 / MDMX regulation | Fenbendazole |
| Mitotic resistance | Tubulin / spindle vulnerability | Mebendazole, fenbendazole |
| PAK1-driven signaling | PAK1-associated survival signaling | Ivermectin |
| YAP-driven persistence | Hippo/YAP signaling | Ivermectin |
| Wnt-driven stemness | Wnt/β-catenin signaling | Ivermectin, niclosamide |
| STAT3 survival signaling | STAT3 inhibition | Niclosamide |
| AR-V7-mediated resistance | Androgen-receptor variant signaling | Niclosamide |
| Glycolytic dependence | HK2 / glucose metabolism | Fenbendazole |
| OXPHOS dependence | Complex III / mitochondrial respiration | Atovaquone |
| Tumor hypoxia | Reduced oxygen consumption | Atovaquone |
| Dense tumor stroma | Stromal / desmoplastic effects | Mebendazole |
This should not be interpreted as evidence that these drugs overcome the listed resistance mechanisms in patients. It is a map of research hypotheses.
10. Comparative Cancer-Type Map
| Cancer Type | Fenbendazole | Mebendazole | Ivermectin | Niclosamide | Atovaquone | Key Research Phenotypes |
|---|---|---|---|---|---|---|
| NSCLC | KRAS, p53, metabolism | Tubulin / mitosis | Wnt / Akt-mTOR signaling | Metabolic / signaling hypotheses | Hypoxia / OXPHOS | KRAS, TP53, HK2, hypoxia |
| Melanoma | p53 / MDM2 / MDMX | Tubulin / Bcl-2 | Wnt / stemness | Wnt / STAT3 | Experimental | TP53-WT, MDM2/MDMX, Bcl-2, Wnt |
| Breast cancer | p53 / metabolism | Tubulin | PAK1 / stemness | Wnt / STAT3 | OXPHOS | TP53-WT, HK2, PAK1, metabolism |
| Pancreatic cancer | Limited biomarker-specific evidence | KRAS / stroma | Wnt / Akt-mTOR | Wnt / STAT3 | Hypoxia / metabolism | KRAS, TP53, CDKN2A, desmoplasia |
| Glioblastoma | Experimental | Tubulin / kinase pathways | Experimental | Wnt / STAT3 | Experimental | Cell-cycle, MAPK14, BBB / PK |
| Gastric cancer | Limited | Experimental | YAP1 / Hippo | Wnt / STAT3 | Experimental | YAP1, Wnt, stemness |
| Colorectal cancer | Experimental | Experimental repositioning | Wnt | Wnt / STAT3 | Metabolic / hypoxia | Wnt, KRAS, BRAF, metabolism |
| Prostate cancer | Limited | Experimental | Signaling / resistance | AR-V7 / Wnt | Experimental | AR-V7, androgen resistance |
| Ovarian cancer | Experimental | Experimental | Wnt / Akt-mTOR | Wnt / mTOR / STAT3 | Metabolic | Wnt, mTOR, STAT3, stemness |
11. The Five-Drug Oncology Architecture
The five compounds can be organized into a systems-level framework rather than a simple ranking.
This structure is more useful for a Cancer Knowledge Graph because it supports many-to-many relationships:
Cancer → Biomarker → Pathway → Resistance Mechanism → Drug Hypothesis → Combination Hypothesis → Evidence Level
12. Highest-Priority Research Hypotheses
Rather than ranking the five drugs as though they were competing standard treatments, it is more scientifically useful to rank the drug-biomarker hypotheses.
| Priority | Drug | Composite Research Phenotype | Why It Matters |
|---|---|---|---|
| 1 | Fenbendazole | TP53-WT + MDM2/MDMX-high | Distinctive p53-regulatory experimental signal. |
| 2 | Fenbendazole | KRAS-mutant NSCLC + glycolytic phenotype | Combines genotype and metabolic biology. |
| 3 | Atovaquone | Highly hypoxic ± OXPHOS-dependent tumor | Supported by human pharmacodynamic data in NSCLC. |
| 4 | Niclosamide | Wnt-high + treatment-resistant phenotype | Repeated Wnt pathway evidence across experimental models. |
| 5 | Niclosamide | AR-V7 / treatment-resistant CRPC | Mechanistically compelling but limited by exposure/formulation challenges. |
| 6 | Mebendazole | High proliferative / tubulin-dependent tumor | Strong direct microtubule rationale. |
| 7 | Ivermectin | PAK1-high / STAT3-active phenotype | Distinct signaling-network hypothesis. |
| 8 | Atovaquone | Hypoxic tumor receiving radiation | Potential radiosensitizing logic; efficacy remains investigational. |
| 9 | Mebendazole | KRAS-driven pancreatic cancer + desmoplasia | Combines malignant and stromal biology. |
| 10 | Ivermectin | YAP1-high gastric cancer | Drug-specific experimental pathway evidence. |
↔ Swipe the table sideways to see all columns on mobile.
These rankings are research priorities, not treatment recommendations.
13. Pharmacology and Translational Limitations
13.1 The concentration problem
One of the biggest problems in drug repurposing is the difference between an experimentally active concentration and a safely achievable human concentration.
A compound may look spectacular in a cell culture dish while requiring concentrations that cannot be reached in human tumors without unacceptable toxicity.
The conventional niclosamide experience is a particularly clear example. The phase I trial in prostate cancer found that tolerable exposure was insufficient to reliably reproduce the concentrations associated with preclinical activity.
13.2 Tumor penetration
Plasma concentration is not the same as intratumoral concentration. Drug distribution into tumors may be influenced by perfusion, extracellular matrix, pH, protein binding, transporters and regional hypoxia.
13.3 Cancer heterogeneity
Even tumors carrying the same driver mutation may differ in lineage, co-mutation profile and metabolic state.
Therefore:
13.4 Biomarker versus mechanism
A molecular pathway can be involved in a drug's mechanism without being a clinically useful predictive biomarker.
For example, Wnt signaling may be affected experimentally by multiple compounds, but that does not mean “Wnt-positive cancer” is a validated indication for any of them.
13.5 Combination complexity
Repurposed drugs are frequently proposed in combinations. This introduces additional variables: overlapping toxicity, CYP interactions, altered exposure, treatment sequencing and the possibility that a combination could antagonize rather than synergize.
Combination hypotheses therefore require the same rigorous testing as new targeted therapies.
14. What Would Clinical Validation Require?
For these compounds to progress from interesting repurposing hypotheses to precision-oncology tools, several steps are needed.
| Development Stage | Question |
|---|---|
| 1. Molecular profiling | Does the proposed biomarker identify a reproducible biological subgroup? |
| 2. Preclinical validation | Does the drug selectively affect biomarker-defined models? |
| 3. Pharmacokinetics | Can active concentrations be achieved safely in humans? |
| 4. Pharmacodynamics | Does the drug actually engage the proposed target or phenotype in human tumors? |
| 5. Early clinical trials | Is there evidence of safety, target engagement and a reproducible antitumor signal? |
| 6. Biomarker-enriched trials | Do biomarker-selected patients perform better than unselected populations? |
| 7. Randomized trials | Does the strategy improve clinically meaningful outcomes compared with standard care? |
This progression is particularly important for repurposed medicines because their existing approval for another disease can create a false impression that the oncology indication is already established.
15. Conclusion
Fenbendazole, mebendazole, ivermectin, niclosamide and atovaquone should not be treated as interchangeable “anticancer antiparasitic drugs.”
Their experimental oncology identities are substantially different.
| Drug | Primary Experimental Identity | Most Interesting Biomarker / Phenotype Layer |
|---|---|---|
| Fenbendazole | Multi-pathway stressor involving p53 regulation, microtubules and metabolism | TP53-WT, MDM2/MDMX, KRAS, HK2 |
| Mebendazole | Tubulin-centered antiproliferative agent with additional apoptotic, kinase and stromal effects | Mitotic vulnerability, MAPK14, KRAS-driven pancreatic models, stroma |
| Ivermectin | Signaling-network modulator | PAK1, YAP1, Wnt, PI3K/Akt/mTOR, stem-like phenotypes |
| Niclosamide | Multi-pathway signaling and metabolic modulator | Wnt, STAT3, AR-V7, mTOR, mitochondrial metabolism |
| Atovaquone | Mitochondrial complex III / OXPHOS and tumor-microenvironment modifier | Hypoxia, OXPHOS dependence, tumor oxygenation |
The most important conceptual expansion is the addition of tumor phenotype alongside molecular biomarkers.
Atovaquone illustrates why this matters. A patient does not necessarily need to have a particular mutation for a hypoxia-modifying strategy to be biologically relevant. The tumor's oxygenation state and mitochondrial dependence can potentially become measurable features of treatment selection.
Niclosamide illustrates a different lesson: a compelling molecular target is not enough if pharmacokinetics prevent adequate tumor exposure.
Fenbendazole illustrates the potential value of combining genotype with pathway state, particularly TP53-WT with MDM2/MDMX elevation.
Mebendazole illustrates the continuing importance of cell division and tumor-stromal biology.
Ivermectin illustrates the complexity of network biology, in which PAK1, YAP1, Wnt and Akt/mTOR can converge on survival and stemness.
Taken together, these drugs provide a useful case study in how precision oncology should approach repurposing:
For patients and families, these distinctions matter. Experimental biology can be valuable, particularly when conventional treatment options become limited, but promising mechanisms, laboratory activity, patient anecdotes and validated clinical efficacy are not the same thing.
16. Frequently Asked Questions
Is fenbendazole a proven cancer treatment?
No. Fenbendazole has experimental anticancer activity in laboratory models, including work involving p53 regulation and metabolism, but it does not have a validated anticancer indication or a prospectively validated predictive biomarker.
Is mebendazole interchangeable with fenbendazole?
No. Both are benzimidazole anthelmintics and both can affect microtubules, but their downstream mechanisms and experimental cancer evidence differ. Mebendazole has particularly strong research around tubulin, mitotic arrest and additional stromal and kinase mechanisms.
What cancer biomarker is most interesting for fenbendazole?
One of the most distinctive experimental hypotheses is TP53 wild-type cancer with elevated MDM2 and/or MDMX, based on experimental reductions in these p53 negative regulators and increased p53/p21 activity. This remains preclinical.
What biomarkers are being investigated for ivermectin?
Experimental literature has focused on PAK1, YAP1/Hippo, Wnt/β-catenin and PI3K/Akt/mTOR signaling, as well as cancer stem-like phenotypes. None is a validated clinical predictive biomarker for ivermectin therapy.
What makes niclosamide interesting in cancer research?
Niclosamide has been studied for effects on Wnt/β-catenin, STAT3, mTOR, NF-κB, Notch and mitochondrial biology. In prostate cancer, AR-V7 has been a particularly notable resistance-related research axis.
Why did niclosamide encounter problems in prostate-cancer trials?
One phase I study found that conventional oral niclosamide could not be escalated beyond 500 mg three times daily without dose-limiting toxicity, and plasma concentrations were not consistently above preclinical thresholds. The study was closed for futility.
Why is atovaquone interesting for cancer?
Atovaquone inhibits mitochondrial complex III and can reduce oxygen consumption. A clinical NSCLC study found reduced tumor hypoxic volume in many treated patients and reduced hypoxia-related gene expression, providing human pharmacodynamic evidence rather than proof of cancer-treatment efficacy.
Could atovaquone improve radiation or immunotherapy?
That is an investigational hypothesis. Because hypoxia can contribute to treatment resistance, reducing tumor hypoxia may theoretically improve the effectiveness of other therapies. Preclinical work has explored these combinations, but clinical efficacy has not been established.
Does a positive biomarker mean a patient should take one of these drugs?
No. A research biomarker does not automatically translate into a treatment indication. Clinical use would require evidence of target engagement, appropriate exposure, safety and meaningful clinical benefit in biomarker-defined patients.
Are these drugs suitable replacements for standard cancer therapy?
No. The evidence reviewed here does not justify replacing, delaying or discontinuing evidence-based cancer treatment.
17. Scientific References
The following references are selected primary studies and authoritative reviews relevant to the mechanisms discussed in this article.
Mrkvová Z, Uldrijan S, Pombinho A, et al. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells. Molecules. 2019;24(11):2152.
PubMed PMID: 31181622
DOI: 10.3390/molecules24112152
Sasaki JI, Ramesh R, Chada S, et al. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Molecular Cancer Therapeutics. 2002.
PubMed PMID: 12479701
Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer.
PubMed PMID: 34262644
Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin.
PubMed PMID: 32021111
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.
PubMed PMID: 29511601
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
PubMed PMID: 24732808
Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells.
PubMed PMID: 22237038
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
PubMed PMID: 29856824
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer.
PubMed PMID: 33737681
Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
PubMed PMID: 27888804
Fiorillo M, Lamb R, Tanowitz HB, et al. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget. 2016;7(23):34084-34099.
PubMed PMID: 27136895
DOI: 10.18632/oncotarget.9122
Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer.
PubMed PMID: 33597271
Ivermectin-related reviews covering PAK1, Wnt/TCF, Hippo/YAP, Akt/mTOR, apoptosis, autophagy and cancer stem-like biology.
PubMed PMID: 32021111
.png)
.png)
.png)
Comments
Post a Comment